ATE185600T1 - Lymphozytenaktivierungsantigen hb15 ein mitglied der immunglobulin superfamilie - Google Patents

Lymphozytenaktivierungsantigen hb15 ein mitglied der immunglobulin superfamilie

Info

Publication number
ATE185600T1
ATE185600T1 AT93910619T AT93910619T ATE185600T1 AT E185600 T1 ATE185600 T1 AT E185600T1 AT 93910619 T AT93910619 T AT 93910619T AT 93910619 T AT93910619 T AT 93910619T AT E185600 T1 ATE185600 T1 AT E185600T1
Authority
AT
Austria
Prior art keywords
lymphocyte activation
activation antigen
immunolobulin
superfamily
disclosed
Prior art date
Application number
AT93910619T
Other languages
English (en)
Inventor
Thomas F Tedder
Liang-Ji Zhou
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE185600T1 publication Critical patent/ATE185600T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT93910619T 1992-04-17 1993-04-14 Lymphozytenaktivierungsantigen hb15 ein mitglied der immunglobulin superfamilie ATE185600T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/870,029 US5316920A (en) 1992-04-17 1992-04-17 Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily

Publications (1)

Publication Number Publication Date
ATE185600T1 true ATE185600T1 (de) 1999-10-15

Family

ID=25354648

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93910619T ATE185600T1 (de) 1992-04-17 1993-04-14 Lymphozytenaktivierungsantigen hb15 ein mitglied der immunglobulin superfamilie

Country Status (10)

Country Link
US (1) US5316920A (de)
EP (1) EP0636176B1 (de)
JP (2) JP3973167B2 (de)
AT (1) ATE185600T1 (de)
AU (1) AU685745B2 (de)
BR (1) BR9306344A (de)
CA (1) CA2118309C (de)
DE (1) DE69326759T2 (de)
NO (1) NO943915L (de)
WO (1) WO1993021318A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710262A (en) * 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
US5534430A (en) * 1993-08-31 1996-07-09 Hitachi Chemical Company Limited Cell strain capable of multiplying an Epstein-Barr virus
WO1997029781A1 (en) * 1996-02-15 1997-08-21 Immunex Corporation Methods and compositions for modulating an immune response
US5849589A (en) * 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
WO1998023747A2 (en) * 1996-11-27 1998-06-04 Schering Corporation Isolated mammalian dendritic cell genes; related reagents
US6361939B1 (en) 1996-11-27 2002-03-26 Schering Corporation Isolated mammalian dendritic cell genes; related reagents
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
US6228640B1 (en) 1997-02-07 2001-05-08 Cem Cezayirli Programmable antigen presenting cell of CD34 lineage
US6251665B1 (en) 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US6210672B1 (en) 1998-10-20 2001-04-03 Torrey Pines Institute For Molecular Studies Topical immunostimulation to induce Langerhans cell migration
US7229621B2 (en) 1998-10-20 2007-06-12 Torrey Pines Institute For Molecular Studies Method to enhance the immunogenicity of an antigen
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
CA2466845A1 (en) * 2001-11-21 2003-06-05 Fred Ramsdell Manipulation of cytokine levels using cd83 gene products
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
AU2002950779A0 (en) * 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
EP1422241A1 (de) * 2002-11-19 2004-05-26 Alexander Steinkasserer Verwendung der löslichen Formen des CD83 und dafür kodierender Nukleinsäuren zur Behandlung oder Vorbeugung von Krankheiten
EP2258724A1 (de) 2002-11-21 2010-12-08 Celltech R & D, Inc. Modulierung von Immunantworten mittels multimeriserter Anti-CD83 Antikörper
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
CN101484461B (zh) 2006-08-18 2014-09-17 阿哥斯医疗公司 Cd83在联合治疗中的用途
ES2425780T3 (es) 2007-06-15 2013-10-17 Panasonic Corporation Aparato de comunicación inalámbrica y procedimiento de difusión de señal de respuesta
KR101679084B1 (ko) * 2008-05-23 2016-11-24 아고스 쎄라퓨틱스, 인코포레이티드 신규 가용성 ｃｄ83 폴리펩티드, 제형 및 사용 방법
PT2951208T (pt) 2013-02-01 2019-12-30 Univ California Anticorpos anti-cd83 e sua utilização
US10870704B2 (en) 2014-10-23 2020-12-22 Kira Biotech Pty Limited CD83 binding proteins and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2010321C (en) * 1989-02-21 2004-04-06 Thomas F. Tedder Lymphocyte-associated cell surface protein
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
WO1992001049A2 (en) * 1990-07-13 1992-01-23 The General Hospital Corporation Cd53 cell surface antigen and use thereof

Also Published As

Publication number Publication date
EP0636176A1 (de) 1995-02-01
CA2118309C (en) 2000-06-13
DE69326759T2 (de) 2000-03-02
JP2007159580A (ja) 2007-06-28
US5316920A (en) 1994-05-31
EP0636176B1 (de) 1999-10-13
AU685745B2 (en) 1998-01-29
CA2118309A1 (en) 1993-10-28
BR9306344A (pt) 1998-06-30
JP3973167B2 (ja) 2007-09-12
DE69326759D1 (de) 1999-11-18
AU4104893A (en) 1993-11-18
NO943915D0 (no) 1994-10-14
JPH09508781A (ja) 1997-09-09
WO1993021318A1 (en) 1993-10-28
NO943915L (no) 1994-12-09

Similar Documents

Publication Publication Date Title
DE69326759D1 (de) Lymphozytenaktivierungsantigen hb15 ein mitglied der immunglobulin superfamilie
Fernandez-Botran et al. Soluble cytokine receptors: their roles in immunoregulation, disease, and therapy
Germann et al. Interleukin‐12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells
Le Garff‐Tavernier et al. Human NK cells display major phenotypic and functional changes over the life span
ATE309360T1 (de) Vaskularer endothelialer wachstumsfaktor 2
Webb et al. Putative role for interleukin‐7 in the maintenance of the recirculating naive CD4+ T‐cell pool
AU2349697A (en) Monoclonal antibodies against the interferon receptor with neutralizing activity against type I interferon
DE69034116D1 (de) Hemmung der anheftung von lymphozyten an das gefässendothelium mittels einer neuen extrazellulärer matrixrezeptor-ligand-wechselwirkung
DE69736184D1 (de) Antagonisten von g protein-gekoppelten rezeptoren
IT8719276A0 (it) Componente di catalizzatore e catalizzatore per la polimerizzazione dell'etilene o la co-polimerizzazione dell-etilene con alfa-olefine.
ATE306549T1 (de) C-c ckr-1, ein c-c chemokin rezeptor
DE69032816D1 (de) Verwendung von oncostatin m zur suppression von mhc antigenen
Klaus et al. A re-evaluation of the role of C3 in B-cell activation
Roberts et al. Mesenchymal cells stimulate human intestinal intraepithelial lymphocytes
Schwab et al. Defective expression of high affinity IL-2 receptors on activated T cells from aged humans
IT8420139A0 (it) Catalizzatori per la omo e copolimerizzazione dell'etilene e polimeri ottenuti.
Molteni et al. Increased interferon-gamma (IFN-γ) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon
EP0097453A3 (en) Alicyclic substituted oxazolidine-2,4-diones having hypoglycemic activity
Qian et al. NK 1.1− CD 4+ NKG 2D+ T cells suppress DSS‐induced colitis in mice through production of TGF‐β
NO174110C (no) Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet
Pollack et al. Inhibition of antibody-dependent cellular cytotoxicity by autologous lymph node cells
Mosmann et al. Heterogeneity of mouse helper T cells and cross-regulation of TH1 and TH2 clones
Gorczynski et al. Individual‐specific (idiotypic) T‐B cell interactions regulating the production of anti‐2, 4, 6‐trinitrophenyl antibody. I. Generation of suppressor T cells and antibody directed against immunocompetent cells
DE69131248D1 (de) Inhibition der ausscheidung von natrium durch die na-k-atpase
Rhodes‐Feuillette et al. Presence of pH2‐Sensitive Circulating Interferon Among Callithrix jacchus Marmosets

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties